• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MELD3.0 评分预测经颈静脉肝内门体分流术创建后肝硬化患者的生存。

MELD 3.0 Score for Predicting Survival in Patients with Cirrhosis After Transjugular Intrahepatic Portosystemic Shunt Creation.

机构信息

Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu, 610041, Sichuan, China.

Department of Gastroenterology, The Third Hospital of Mianyang, 190 Jiannan Road, Mianyang, 612000, Sichuan, China.

出版信息

Dig Dis Sci. 2023 Jul;68(7):3185-3192. doi: 10.1007/s10620-023-07834-3. Epub 2023 Jan 30.

DOI:10.1007/s10620-023-07834-3
PMID:36715817
Abstract

BACKGROUND AND AIMS

The selection of appropriate candidates for transjugular intrahepatic portosystemic shunt (TIPS) is important and challenging. To validate the Model for End-Stage Liver Disease (MELD) 3.0 in predicting mortality in patients with cirrhosis after TIPS creation.

METHODS

A total of 855 consecutive patients with cirrhosis from December 2011 to October 2019 who underwent TIPS placement were retrospectively reviewed. The prognostic value of the MELD 3.0, MELD, MELD-Na, Child-Pugh and FIPS score was assessed using Harrell's C concordance index (c-index). The Hosmer-Lemeshow test was used to test the goodness of fit of all models and the calibration plot was drawn.

RESULTS

The c-index of the MELD 3.0 in predicting 3-month mortality was 0.727 (0.645-0.808), which were significantly superior to the MELD (0.663 [0.565-0.761]; P = 0.015), MELD-Na (0.672 [0.577-0.768]; P = 0.008) and FIPS (0.582 [0.477-0.687]; P = 0.015). The Child-Pugh score reached c-indices of 0.754 (0.673-0.835), 0.720 (0.649-0.792), 0.705 (0.643-0.766) and 0.665 (0.614-0.716) for 3-month, 6-month, 1-year, and 2-year mortality, respectively, which seems comparable to MELD 3.0. A MELD 3.0 of 14 could be used as a cut-off point for discriminating between high- and low-risk patients. The MELD 3.0 could stratify patients with Child-Pugh grade B (log-rank P < 0.001). The Child-Pugh score could stratify patients defined as low risk by MELD 3.0 (log-rank P < 0.001).

CONCLUSIONS

The MELD 3.0 was significantly superior to the MELD, MELD-Na and FIPS scores in predicting mortality in patients with cirrhosis after TIPS creation.

摘要

背景与目的

经颈静脉肝内门体分流术(TIPS)的合适患者选择很重要,也具有挑战性。本研究旨在验证终末期肝病模型(MELD)3.0 预测 TIPS 术后肝硬化患者死亡率的能力。

方法

回顾性分析 2011 年 12 月至 2019 年 10 月期间接受 TIPS 治疗的 855 例连续肝硬化患者的临床资料。采用 Harrell's C 一致性指数(c-index)评估 MELD 3.0、MELD、MELD-Na、Child-Pugh 和 FIPS 评分预测 TIPS 术后 3 个月死亡率的预后价值。采用 Hosmer-Lemeshow 检验评估所有模型的拟合优度,并绘制校准图。

结果

MELD 3.0 预测 3 个月死亡率的 c-index 为 0.727(0.645-0.808),显著优于 MELD(0.663 [0.565-0.761];P=0.015)、MELD-Na(0.672 [0.577-0.768];P=0.008)和 FIPS(0.582 [0.477-0.687];P=0.015)。Child-Pugh 评分预测 3 个月、6 个月、1 年和 2 年死亡率的 c-index 分别为 0.754(0.673-0.835)、0.720(0.649-0.792)、0.705(0.643-0.766)和 0.665(0.614-0.716),与 MELD 3.0 相似。14 分的 MELD 3.0 可作为区分高危和低危患者的截断值。MELD 3.0 可对 Child-Pugh 分级 B 的患者进行分层(log-rank P<0.001)。Child-Pugh 评分可对 MELD 3.0 定义的低危患者进行分层(log-rank P<0.001)。

结论

MELD 3.0 显著优于 MELD、MELD-Na 和 FIPS 评分,可预测 TIPS 术后肝硬化患者的死亡率。

相似文献

1
MELD 3.0 Score for Predicting Survival in Patients with Cirrhosis After Transjugular Intrahepatic Portosystemic Shunt Creation.MELD3.0 评分预测经颈静脉肝内门体分流术创建后肝硬化患者的生存。
Dig Dis Sci. 2023 Jul;68(7):3185-3192. doi: 10.1007/s10620-023-07834-3. Epub 2023 Jan 30.
2
Validating the prognostic value of Freiburg index of posttransjugular intrahepatic portosystemic shunt survival score and classic scores in Chinese patients with implantation of transjugular intrahepatic portosystemic shunt.验证 Freiburg 经颈静脉肝内门体分流术生存评分和经典评分在中国人行经颈静脉肝内门体分流术患者中的预后价值。
Eur J Gastroenterol Hepatol. 2022 Oct 1;34(10):1074-1080. doi: 10.1097/MEG.0000000000002427. Epub 2022 Aug 24.
3
Inclusion of sarcopenia improves the prognostic value of MELD score in patients after transjugular intrahepatic portosystemic shunt.纳入肌肉减少症可提高经颈静脉肝内门体分流术后患者 MELD 评分的预后价值。
Eur J Gastroenterol Hepatol. 2022 Sep 1;34(9):948-955. doi: 10.1097/MEG.0000000000002391. Epub 2022 May 23.
4
Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures.在经颈静脉肝内门体分流术(TIPS)前进行风险分层时,应用终末期肝病模型评分(而非终末期肝病模型钠评分)。
Eur J Gastroenterol Hepatol. 2021 Apr 1;33(4):541-546. doi: 10.1097/MEG.0000000000001760.
5
FIPS Score for Prediction of Survival After TIPS Placement: External Validation and Comparison With Traditional Risk Scores in a Cohort of Chinese Patients With Cirrhosis.经颈静脉肝内门体分流术(TIPS)后生存预测的 FIPS 评分:在中国肝硬化患者队列中的外部验证及与传统风险评分的比较。
AJR Am J Roentgenol. 2022 Aug;219(2):255-267. doi: 10.2214/AJR.21.27301. Epub 2022 Feb 9.
6
Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.经颈静脉肝内门体分流术后肝性脑病预测的吲哚菁绿-R15、Child-Pugh 评分和终末期肝病模型评分的对比研究。
World J Gastroenterol. 2021 Feb 7;27(5):416-427. doi: 10.3748/wjg.v27.i5.416.
7
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.使用新型弗赖堡经颈静脉肝内门体分流术后生存指数优化经颈静脉肝内门体分流术后生存预测。
J Hepatol. 2021 Jun;74(6):1362-1372. doi: 10.1016/j.jhep.2021.01.023. Epub 2021 Jan 26.
8
Combination of Model for End-Stage Liver Disease (MELD) and Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt (TIPS).模型终末期肝病评分(MELD)和肌肉减少症联合预测经颈静脉肝内门体分流术(TIPS)后的死亡率。
Dig Liver Dis. 2024 Sep;56(9):1544-1550. doi: 10.1016/j.dld.2024.03.003. Epub 2024 Mar 29.
9
Different scoring systems in predicting survival in Chinese patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt.不同评分系统对接受经颈静脉肝内门体分流术的中国肝硬化患者生存情况的预测
Eur J Gastroenterol Hepatol. 2014 Aug;26(8):853-60. doi: 10.1097/MEG.0000000000000134.
10
Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt.经颈静脉肝内门体分流术患者 CLIF-C AD 评分的预后价值。
Hepatol Commun. 2021 Jan 5;5(4):650-660. doi: 10.1002/hep4.1654. eCollection 2021 Apr.

引用本文的文献

1
Comment on "Prognostic Performance of Model for End-Stage Liver Disease (MELD) 3.0 for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation".关于“终末期肝病模型(MELD)3.0在经颈静脉肝内门体分流术(TIPS)创建中的预后性能”的评论
Cardiovasc Intervent Radiol. 2025 Aug 26. doi: 10.1007/s00270-025-04148-x.
2
Comments on: "Prognostic Performance of Model for End-Stage Liver Disease (MELD) 3.0 for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation" by Michimoto et al. (2025).对Michimoto等人(2025年)所著《终末期肝病模型(MELD)3.0用于经颈静脉肝内门体分流术(TIPS)创建的预后性能》的评论
Cardiovasc Intervent Radiol. 2025 Aug 26. doi: 10.1007/s00270-025-04176-7.
3
Prognostic Performance of Model for End-Stage Liver Disease (MELD) 3.0 for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation.
终末期肝病模型(MELD)3.0在经颈静脉肝内门体分流术(TIPS)创建中的预后性能。
Cardiovasc Intervent Radiol. 2025 Jul 14. doi: 10.1007/s00270-025-04116-5.
4
The unwell patient with advanced chronic liver disease: when to use each score?患有晚期慢性肝病的不适患者:何时使用每种评分?
BMC Med. 2025 Jul 9;23(1):413. doi: 10.1186/s12916-025-04185-w.
5
Improved Discrimination and Predictive Ability of Novel Prognostic Scores for Long-term Mortality in Hospitalized Patients with Cirrhosis.新型预后评分对肝硬化住院患者长期死亡率的鉴别能力和预测能力的改善
J Clin Transl Hepatol. 2025 Jun 28;13(6):484-492. doi: 10.14218/JCTH.2025.00004. Epub 2025 Mar 11.
6
The Development and Appraisal of MELD 3.0 in Liver Diseases: Good Things Never Come Easy.终末期肝病模型(MELD)3.0在肝脏疾病中的发展与评估:好事多磨。
J Clin Transl Hepatol. 2025 Jan 28;13(1):62-68. doi: 10.14218/JCTH.2024.00303. Epub 2024 Nov 12.
7
Postoperative, but Not Preoperative, MELD-3.0 Prognosticates 3-Month Procedural Success in Patients Undergoing Orthotopic Heart Transplantation.术后而非术前的终末期肝病模型(MELD)-3.0评分可预测原位心脏移植患者3个月的手术成功率。
J Clin Med. 2024 Sep 28;13(19):5816. doi: 10.3390/jcm13195816.
8
The Value of Neutrophil-to-Lymphocyte Ratio in Predicting Mortality After Transjugular Intrahepatic Portosystemic Shunt Placement.中性粒细胞与淋巴细胞比值在预测经颈静脉肝内门体分流术术后死亡率中的价值
J Inflamm Res. 2024 Aug 1;17:5211-5221. doi: 10.2147/JIR.S467583. eCollection 2024.
9
MELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi-ethnic population.MELD 3.0在预测肝硬化患者死亡率方面优于MELDNa和MELD:多民族人群的外部验证
JGH Open. 2024 Jun 2;8(6):e13098. doi: 10.1002/jgh3.13098. eCollection 2024 Jun.